Guggenheim Capital’s Aimmune Therapeutics AIMT Stock Holding History

Guggenheim Capital’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-39,629	Closed	-$1.36M	–	2159
2020 Q3	$1.36M	Buy	+39,629	New	+$844K	0.01%	1067
2020 Q1	–	Sell	-10,008	Closed	-$335K	–	2068
2019 Q4	$335K	Sell	10,008 -140	-1%	-$3.91K	﹤0.01%	1773
2019 Q3	$212K	Sell	10,148 -978	-9%	-$20K	﹤0.01%	1990
2019 Q2	$232K	Sell	11,126 -232	-2%	-$4.78K	﹤0.01%	1977
2019 Q1	$254K	Buy	11,358 +962	+9%	+$22.6K	﹤0.01%	1973
2018 Q4	$249K	Buy	10,396 +3,062	+42%	+$79.2K	﹤0.01%	1980
2018 Q3	$200K	Buy	+7,334	New	+$207K	﹤0.01%	2334

Guggenheim Capital's AIMT Position: Q4 2020 in Review

Guggenheim Capital sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 39,629 shares — an estimated $1.36M sold.

Guggenheim Capital first reported a position in AIMT in Q3 2018 and held it in 7 quarters. The position peaked at $1.36M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Guggenheim Capital reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Guggenheim Capital sold 39,629 Aimmune Therapeutics shares in Q4 2020, an estimated $1.36M.
Guggenheim Capital first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 7 quarters.
Guggenheim Capital's Aimmune Therapeutics position peaked at $1.36M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Guggenheim Capital's 13F filing for Q4 2020, filed 16 Feb 2021.